GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Float Percentage Of Total Shares Outstanding

Cue Biopharma (Cue Biopharma) Float Percentage Of Total Shares Outstanding : 97.01% (As of May. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cue Biopharma's float shares is 47.19 Mil. Cue Biopharma's total shares outstanding is 48.64 Mil. Cue Biopharma's float percentage of total shares outstanding is 97.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cue Biopharma's Insider Ownership is 4.50%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cue Biopharma's Institutional Ownership is 16.12%.

Cue Biopharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cue Biopharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=47.19/48.64
=97.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma (Cue Biopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
VERU VICP NKTR ADVM CMRX AAGH ACHV HRTX SGMT GLYC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
1UC:Germany 1UC:Germany
Address
40 Guest Street, Boston, MA, USA, 02135
Website
https://www.cuebiopharma.com
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.
Executives
Anish Suri officer: President and CSO 40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri director, officer: CEO 40 GUEST STREET, BOSTON MA 02135
Pamela Garzone director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener director 40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti officer: Chief Medical Officer C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn officer: Chief Business Officer C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar officer: CFO 40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta officer: Chief Medical Officer C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin officer: SVP, General Counsel and Sec 40 GUEST STREET, BOSTON MA 02135
Tamar D Howson director
Barry J. Simon director 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll director